πŸ‡ΊπŸ‡Έ FDA
Patent

US 11584736

Heterocyclic P2Y14 receptor antagonists

granted A61PA61P11/06A61P13/12

Quick answer

US patent 11584736 (Heterocyclic P2Y14 receptor antagonists) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61P, A61P11/06, A61P13/12, A61P29/00